Cargando…
Prospective multicenter real-world RAS mutation comparison between OncoBEAM-based liquid biopsy and tissue analysis in metastatic colorectal cancer
BACKGROUND: Liquid biopsy offers a minimally invasive alternative to tissue-based evaluation of mutational status in cancer. The goal of the present study was to evaluate the aggregate performance of OncoBEAM RAS mutation analysis in plasma of colorectal cancer (CRC) patients at 10 hospital laborato...
Autores principales: | , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6288144/ https://www.ncbi.nlm.nih.gov/pubmed/30467411 http://dx.doi.org/10.1038/s41416-018-0293-5 |
_version_ | 1783379740822863872 |
---|---|
author | García-Foncillas, Jesús Tabernero, Josep Élez, Elena Aranda, Enrique Benavides, Manuel Camps, Carlos Jantus-Lewintre, Eloisa López, Rafael Muinelo-Romay, Laura Montagut, Clara Antón, Antonio López, Guillermo Díaz-Rubio, Eduardo Rojo, Federico Vivancos, Ana |
author_facet | García-Foncillas, Jesús Tabernero, Josep Élez, Elena Aranda, Enrique Benavides, Manuel Camps, Carlos Jantus-Lewintre, Eloisa López, Rafael Muinelo-Romay, Laura Montagut, Clara Antón, Antonio López, Guillermo Díaz-Rubio, Eduardo Rojo, Federico Vivancos, Ana |
author_sort | García-Foncillas, Jesús |
collection | PubMed |
description | BACKGROUND: Liquid biopsy offers a minimally invasive alternative to tissue-based evaluation of mutational status in cancer. The goal of the present study was to evaluate the aggregate performance of OncoBEAM RAS mutation analysis in plasma of colorectal cancer (CRC) patients at 10 hospital laboratories in Spain where this technology is routinely implemented. METHODS: Circulating cell-free DNA from plasma was examined for RAS mutations using the OncoBEAM platform at each hospital laboratory. Results were then compared to those obtained from DNA extracted from tumour tissue from the same patient. RESULTS: The overall percentage agreement between plasma-based and tissue-based RAS mutation testing of the 236 participants was 89% (210/236; kappa, 0.770 (95% CI: 0.689–0.852)). Re-analysis of tissue from all discordant cases by BEAMing revealed two false negative and five false positive tumour tissue RAS results, with a final concordance of 92%. Plasma false negative results were found more frequently in patients with exclusive lung metastatic disease. CONCLUSIONS: In this first prospective real-world RAS mutation performance comparison study, a high overall agreement was observed between results obtained from plasma and tissue samples. Overall, these findings indicate that the plasma-based BEAMing assay is a viable solution for rapid delivery of RAS mutation status to determine mCRC patient eligibility for anti-EGFR therapy. |
format | Online Article Text |
id | pubmed-6288144 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-62881442019-06-21 Prospective multicenter real-world RAS mutation comparison between OncoBEAM-based liquid biopsy and tissue analysis in metastatic colorectal cancer García-Foncillas, Jesús Tabernero, Josep Élez, Elena Aranda, Enrique Benavides, Manuel Camps, Carlos Jantus-Lewintre, Eloisa López, Rafael Muinelo-Romay, Laura Montagut, Clara Antón, Antonio López, Guillermo Díaz-Rubio, Eduardo Rojo, Federico Vivancos, Ana Br J Cancer Article BACKGROUND: Liquid biopsy offers a minimally invasive alternative to tissue-based evaluation of mutational status in cancer. The goal of the present study was to evaluate the aggregate performance of OncoBEAM RAS mutation analysis in plasma of colorectal cancer (CRC) patients at 10 hospital laboratories in Spain where this technology is routinely implemented. METHODS: Circulating cell-free DNA from plasma was examined for RAS mutations using the OncoBEAM platform at each hospital laboratory. Results were then compared to those obtained from DNA extracted from tumour tissue from the same patient. RESULTS: The overall percentage agreement between plasma-based and tissue-based RAS mutation testing of the 236 participants was 89% (210/236; kappa, 0.770 (95% CI: 0.689–0.852)). Re-analysis of tissue from all discordant cases by BEAMing revealed two false negative and five false positive tumour tissue RAS results, with a final concordance of 92%. Plasma false negative results were found more frequently in patients with exclusive lung metastatic disease. CONCLUSIONS: In this first prospective real-world RAS mutation performance comparison study, a high overall agreement was observed between results obtained from plasma and tissue samples. Overall, these findings indicate that the plasma-based BEAMing assay is a viable solution for rapid delivery of RAS mutation status to determine mCRC patient eligibility for anti-EGFR therapy. Nature Publishing Group UK 2018-11-23 2018-12-11 /pmc/articles/PMC6288144/ /pubmed/30467411 http://dx.doi.org/10.1038/s41416-018-0293-5 Text en © The Author(s) 2018 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Article García-Foncillas, Jesús Tabernero, Josep Élez, Elena Aranda, Enrique Benavides, Manuel Camps, Carlos Jantus-Lewintre, Eloisa López, Rafael Muinelo-Romay, Laura Montagut, Clara Antón, Antonio López, Guillermo Díaz-Rubio, Eduardo Rojo, Federico Vivancos, Ana Prospective multicenter real-world RAS mutation comparison between OncoBEAM-based liquid biopsy and tissue analysis in metastatic colorectal cancer |
title | Prospective multicenter real-world RAS mutation comparison between OncoBEAM-based liquid biopsy and tissue analysis in metastatic colorectal cancer |
title_full | Prospective multicenter real-world RAS mutation comparison between OncoBEAM-based liquid biopsy and tissue analysis in metastatic colorectal cancer |
title_fullStr | Prospective multicenter real-world RAS mutation comparison between OncoBEAM-based liquid biopsy and tissue analysis in metastatic colorectal cancer |
title_full_unstemmed | Prospective multicenter real-world RAS mutation comparison between OncoBEAM-based liquid biopsy and tissue analysis in metastatic colorectal cancer |
title_short | Prospective multicenter real-world RAS mutation comparison between OncoBEAM-based liquid biopsy and tissue analysis in metastatic colorectal cancer |
title_sort | prospective multicenter real-world ras mutation comparison between oncobeam-based liquid biopsy and tissue analysis in metastatic colorectal cancer |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6288144/ https://www.ncbi.nlm.nih.gov/pubmed/30467411 http://dx.doi.org/10.1038/s41416-018-0293-5 |
work_keys_str_mv | AT garciafoncillasjesus prospectivemulticenterrealworldrasmutationcomparisonbetweenoncobeambasedliquidbiopsyandtissueanalysisinmetastaticcolorectalcancer AT tabernerojosep prospectivemulticenterrealworldrasmutationcomparisonbetweenoncobeambasedliquidbiopsyandtissueanalysisinmetastaticcolorectalcancer AT elezelena prospectivemulticenterrealworldrasmutationcomparisonbetweenoncobeambasedliquidbiopsyandtissueanalysisinmetastaticcolorectalcancer AT arandaenrique prospectivemulticenterrealworldrasmutationcomparisonbetweenoncobeambasedliquidbiopsyandtissueanalysisinmetastaticcolorectalcancer AT benavidesmanuel prospectivemulticenterrealworldrasmutationcomparisonbetweenoncobeambasedliquidbiopsyandtissueanalysisinmetastaticcolorectalcancer AT campscarlos prospectivemulticenterrealworldrasmutationcomparisonbetweenoncobeambasedliquidbiopsyandtissueanalysisinmetastaticcolorectalcancer AT jantuslewintreeloisa prospectivemulticenterrealworldrasmutationcomparisonbetweenoncobeambasedliquidbiopsyandtissueanalysisinmetastaticcolorectalcancer AT lopezrafael prospectivemulticenterrealworldrasmutationcomparisonbetweenoncobeambasedliquidbiopsyandtissueanalysisinmetastaticcolorectalcancer AT muineloromaylaura prospectivemulticenterrealworldrasmutationcomparisonbetweenoncobeambasedliquidbiopsyandtissueanalysisinmetastaticcolorectalcancer AT montagutclara prospectivemulticenterrealworldrasmutationcomparisonbetweenoncobeambasedliquidbiopsyandtissueanalysisinmetastaticcolorectalcancer AT antonantonio prospectivemulticenterrealworldrasmutationcomparisonbetweenoncobeambasedliquidbiopsyandtissueanalysisinmetastaticcolorectalcancer AT lopezguillermo prospectivemulticenterrealworldrasmutationcomparisonbetweenoncobeambasedliquidbiopsyandtissueanalysisinmetastaticcolorectalcancer AT diazrubioeduardo prospectivemulticenterrealworldrasmutationcomparisonbetweenoncobeambasedliquidbiopsyandtissueanalysisinmetastaticcolorectalcancer AT rojofederico prospectivemulticenterrealworldrasmutationcomparisonbetweenoncobeambasedliquidbiopsyandtissueanalysisinmetastaticcolorectalcancer AT vivancosana prospectivemulticenterrealworldrasmutationcomparisonbetweenoncobeambasedliquidbiopsyandtissueanalysisinmetastaticcolorectalcancer |